Topline results from the Phase 2 TRAPEDS-1 trial showed that tralokinumab demonstrated favorable pharmacokinetic and safety ...

LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab ...

Eli Lilly Canada Inc. (Lilly Canada) has officially received a long-awaited positive recommendation (reimbursement with ...

What exactly is severe AD? AD is the most common type of eczema. When this eczema becomes severe, a person has patches of skin that are red, swollen, and unbearably itchy. The patches of AD can weep ...

Dupilumab demonstrated robust efficacy, durable benefits, and a favorable safety profile in children with moderate-to-severe ...

Abrocitinib can help achieve minimal disease activity in patients with atopic dermatitis irrespective of previous exposure to ...

Kymera Therapeutics Inc. KYMR shares are trading higher by more than 21% on Thursday as the company has completed enrollment in its BROADEN2 Phase 2b trial for KT-621, a treatment for moderate to ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

A 28-year-old woman presented to her primary care provider with the chief report of persistent itch associated with atopic dermatitis (AD), with itch severity worst on her hands bilaterally. AD was ...

Generation Z (Gen Z) patients present with a higher subjective perception of atopic dermatitis severity than millennial generation patients, according to a study published online July 25 in the ...

Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking ...

Claims-based MarketScan analyses (>11,000 patients) showed moderate-to-severe alopecia areata carried higher atopic dermatitis risk than mild disease (adjusted HR 1.8; 95% CI 1.1–2.8). Baseline atopic ...